Takeda's Edarbi Joins Busy Hypertension Field With Comparative Data
Executive Summary
Takeda Pharmaceutical Company Ltd. secured FDA approval of a new angiotensin II receptor blocker Edarbi (azilsartan) for high blood pressure Feb. 25, but launching an anti-hypertensive in a crowded and highly genericized market will be challenging.
You may also be interested in...
Optimer's Fidaxomicin Among Three NMEs Given Positive Review By Europe's Regulators
EU's scientific advisory panel also recommends approval for Takeda's azilsartan and Tibotec's rilpivirine, and grants positive opinions on new indications for Bayer/Johnson & Johnson's rivaroxaban and Alexion's eculizumab.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.